NCT05086315
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) No drug interventions treatment 1 / 2 recruiting NCT03766126
Lentivirally Redirected CD123 Autologous T Cells in AML treatment 1 active_not_recruiting NCT04678336
CD123 Redirected T Cells for AML in Pediatric Subjects treatment 1 recruiting NCT04716452
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia No drug interventions treatment 1 not_yet_recruiting NCT06372717
A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS treatment 1 / 2 recruiting NCT06017258
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT06128044
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05574608
Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia treatment 0 recruiting NCT05317403
Venetoclax to Augment Epigenetic Modification and Chemotherapy treatment 1 recruiting NCT06150040
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] treatment 1 / 2 recruiting NCT05854966
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 2 not_yet_recruiting NCT05546580
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) treatment 1 recruiting NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS treatment 1 recruiting NCT06459024
Master Framework For Relapse or Refractory Acute Myeloid Leukemia No drug interventions Not Available Not Available not_yet_recruiting NCT05949125
Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 No drug interventions treatment 1 recruiting NCT04347616
Natural Killer-cell Therapy for Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT04914845
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05105152
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML No drug interventions treatment 1 recruiting NCT06281847
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia No drug interventions treatment 1 / 2 not_yet_recruiting NCT06201247
Off-the-shelf CD123 CAR-NK for R/R AML No drug interventions treatment 0 recruiting NCT06125652
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) No drug interventions treatment 1 / 2 recruiting NCT03690154
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML treatment 1 terminated NCT05211570
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT05190471
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) treatment 1 recruiting NCT05506332
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT05488132
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) No drug interventions treatment 1 / 2 recruiting NCT03787498
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome No drug interventions treatment 1 completed NCT04330820
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) treatment 1 / 2 active_not_recruiting NCT06316960
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation treatment 2 recruiting NCT06022003
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia treatment 2 recruiting NCT03850574
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT06007911
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 withdrawn NCT05735184
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML treatment 1 recruiting NCT06307054
CLL-1 CAR-NK Cells for Relapsed/Refractory AML treatment 1 recruiting NCT05226468
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia No drug interventions treatment 1 active_not_recruiting NCT05193448
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE No drug interventions Not Available Not Available completed NCT04310592
Natural Killer Cell (CYNK-001) Infusions in Adults With AML treatment 1 recruiting NCT03516760
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT02675478
Phase 1 Study of Quizartinib treatment 1 completed NCT03128034
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia treatment 1 / 2 suspended NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT01620216
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia treatment 2 terminated NCT04203316
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation treatment 2 recruiting NCT06501196
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome No drug interventions treatment 1 recruiting NCT02070458
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT04752163
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT04158739
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT05010122
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT04354025
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML treatment 2 withdrawn NCT04128748
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT04891757
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies treatment 1 recruiting NCT03670966
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome treatment 1 / 2 suspended NCT01961765
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT01787474
Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT03017820
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma treatment 1 recruiting NCT02397720
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT02109627
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML treatment 1 terminated NCT06418776
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML No drug interventions treatment 3 recruiting NCT04898894
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia treatment 1 recruiting NCT04874194
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 treatment 1 / 2 active_not_recruiting NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy treatment 1 recruiting NCT05320380
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat treatment 1 / 2 withdrawn NCT04562792
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia treatment 2 completed NCT03063944
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy treatment 1 completed NCT06177067
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia treatment 1 recruiting NCT02756572
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms treatment 2 completed NCT05456269
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS treatment 1 withdrawn NCT04915612
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT04196010
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms treatment 1 terminated NCT04526795
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia treatment 1 active_not_recruiting NCT02159495
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm treatment 1 active_not_recruiting NCT03701295
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement treatment 1 / 2 completed NCT02115295
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia treatment 2 recruiting NCT05441514
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 completed NCT06385808
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML treatment Not Available not_yet_recruiting NCT02257138
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia treatment 1 / 2 completed NCT02882321
Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 terminated NCT03519984
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia treatment 1 terminated NCT03513484
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT05222984
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax treatment 1 active_not_recruiting NCT04220684
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML treatment 1 recruiting NCT03041688
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03672539
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome treatment 2 recruiting NCT04188405
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia treatment 2 active_not_recruiting NCT04774393
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT06572631
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor treatment 1 not_yet_recruiting NCT04140487
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm treatment 1 / 2 recruiting NCT04746235
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia treatment 2 recruiting NCT05146739
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane treatment 1 active_not_recruiting NCT06561152
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML treatment 1 / 2 not_yet_recruiting NCT02220985
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD treatment 2 active_not_recruiting NCT02890329
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03683433
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation treatment 2 recruiting NCT03816319
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia treatment 1 not_yet_recruiting NCT03874052
Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 suspended NCT04435691
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT05396859
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia treatment 1 recruiting NCT06399640
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia treatment 1 recruiting NCT03772925
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 active_not_recruiting NCT05028751
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) treatment 1 / 2 terminated NCT06536959
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS treatment 2 recruiting NCT03629171
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia treatment 2 recruiting NCT03953898
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation treatment 2 active_not_recruiting NCT04375631
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia treatment 1 recruiting NCT04975919
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 2 active_not_recruiting NCT03289910
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia treatment 2 active_not_recruiting NCT03471260
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies treatment 1 / 2 recruiting NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome treatment 2 active_not_recruiting NCT04047641
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT04835519
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 / 2 completed NCT06484062
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 and ASTX727 With Venetoclax to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes treatment 1 not_yet_recruiting NCT06454409
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 not_yet_recruiting NCT03983824
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia treatment 1 suspended NCT04797767
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms treatment 1 suspended NCT06222580
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation treatment 1 recruiting NCT03214562
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT03600155
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 active_not_recruiting NCT04207190
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT03247088
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT02392572
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 / 2 recruiting NCT04470947
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies No drug interventions Not Available Not Available recruiting NCT04493164
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 recruiting NCT01892371
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 / 2 completed NCT03009240
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT03132454
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia treatment 1 recruiting NCT04956042
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 / 2 terminated NCT03813147
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT05672147
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia No drug interventions treatment 1 recruiting NCT03969446
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory treatment 1 recruiting NCT05627232
Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT02509546
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 completed NCT05597306
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT04668885
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS No drug interventions treatment 2 active_not_recruiting NCT05263284
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT02649764
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 1 completed NCT03067571
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 terminated NCT04049539
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction treatment 1 / 2 recruiting NCT03390296
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia treatment 1 / 2 completed NCT03745352
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 withdrawn NCT03634228
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia treatment 1 / 2 terminated NCT04146038
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease treatment 2 completed NCT04250051
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT04487106
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome treatment 2 completed NCT04749355
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS treatment 2 active_not_recruiting NCT05456048
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML No drug interventions Not Available Not Available completed NCT05362942
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia treatment 2 not_yet_recruiting NCT04904237
Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. No drug interventions treatment 2 recruiting NCT04893915
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS treatment 2 withdrawn NCT04493099
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML treatment 1 / 2 withdrawn NCT04424147
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML No drug interventions treatment 2 completed NCT04013880
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment 1 / 2 withdrawn NCT04000698
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias No drug interventions treatment 3 unknown_status NCT03881735
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation treatment 2 withdrawn NCT03752138
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia treatment 1 withdrawn NCT03602898
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation treatment 2 withdrawn NCT03557970
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia treatment 2 terminated NCT03291353
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia treatment 0 withdrawn NCT03035422
Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia No drug interventions other Not Available completed NCT02953561
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia treatment 1 / 2 terminated NCT02921061
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS treatment 1 / 2 completed NCT02551718
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia No drug interventions treatment Not Available completed NCT02399917
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia treatment 2 terminated NCT02381548
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia treatment 1 terminated NCT01249430
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT01130506
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT00426205
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies No drug interventions treatment Not Available completed NCT02091245
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML treatment 1 active_not_recruiting NCT03081780
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML No drug interventions treatment 1 completed NCT01464359
T-Cell Depleted Double UCB for Refractory AML treatment 2 terminated